文献速递脊柱关节炎

艾克司单抗治疗对骶髂关节结构改变的影响:非放射学中轴型脊柱关节炎患者16周MRI评估

Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
PubMed 文献 · Lancet Rheumatol · 2022-08-09

COAST-X研究的事后分析纳入266例有基线和16周MRI的非放射学中轴型脊柱关节炎患者,评估艾克司单抗与安慰剂对骶髂关节结构病变的影响。16周时艾克司单抗组侵蚀评分较安慰剂显著降低,脂肪病变和回填评分显著升高,作者认为这提示早期修复过程,但临床相关性尚不明确。

要点

  • 16周时艾克司单抗Q4W和Q2W组侵蚀评分分别降低0.39和0.40,安慰剂组升高0.16。
  • 艾克司单抗组脂肪病变和回填评分升高,安慰剂组降低,组间差异有统计学意义。
  • 结构改变效应在基线骶髂关节有炎症的患者中最明显,但临床相关性尚不明确。

核心结论

  • 非放射学中轴型脊柱关节炎患者接受艾克司单抗治疗16周后,骶髂关节侵蚀较安慰剂显著减少,脂肪病变和回填显著增加,提示艾克司单抗治疗可能带来早期修复过程,但临床相关性尚不明确。

研究设计与样本

  • COAST-X是一项52周、随机、双盲、安慰剂对照、平行组研究,在欧洲、亚洲、北美和南美15个国家107个中心进行。
  • 本研究为事后分析,纳入266例有基线和第16周MRI扫描的非放射学中轴型脊柱关节炎患者。
  • 患者随机分配至安慰剂组或双盲艾克司单抗80 mg每4周(Q4W)或每2周(Q2W)组,起始剂量为80 mg或160 mg。
  • MRI扫描由两名设盲读片者独立使用SPARCC骶髂关节结构评分(SSS)方法评分。
  • 治疗比较采用基于观察病例的协方差分析。

主要发现

  • 从基线至第16周,侵蚀的SPARCC SSS平均变化:艾克司单抗Q4W组-0.39(与安慰剂比较p=0.003),Q2W组-0.40(p=0.002),安慰剂组0.16。
  • 脂肪病变的SPARCC SSS平均变化:艾克司单抗Q4W组0.16(p=0.013),Q2W组0.10(p=0.067),安慰剂组-0.04。
  • 回填的SPARCC SSS平均变化:艾克司单抗Q4W组0.21(p=0.011),Q2W组0.22(p=0.006),安慰剂组-0.10。
  • 强直未见变化。
  • 艾克司单抗与安慰剂对结构改变的影响在基线骶髂关节有炎症的患者中最明显,第16周侵蚀、脂肪病变和回填的变化相互相关。

关键数值与推荐

  • COAST-X注册于ClinicalTrials.gov,注册号NCT02757352。
  • 2016年8月2日至2018年1月29日期间,COAST-X研究共入组303例患者。
  • 303例参与者中290例(96%)完成第16周访视(艾克司单抗Q4W组95例,Q2W组98例,安慰剂组97例)。
  • 266例患者有基线和第16周MRI扫描(艾克司单抗Q4W组85例,Q2W组91例,安慰剂组90例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出临床相关性尚不明确。
  • 本研究为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited understanding regarding the inhibition of structural damage in the sacroiliac joint of patients with non-radiographic axial spondyloarthritis. This study evaluated the effect of the interleukin-17A inhibitor ixekizumab versus placebo on structural lesions in the sacroiliac joints as assessed by MRI at week 16 in patients with non-radiographic axial spondyloarthritis from the COAST-X study. METHODS: COAST-X was a 52-week, randomised, double-blind, placebo-controlled, parallel-group study done at 107 sites in 15 countries in Europe, Asia, North America, and South America. Eligible participants were adults (aged ≥18 years) with active axial spondyloarthritis without definite radiographic sacroiliitis (non-radiographic axial spondyloarthritis), objective signs of inflammation (via MRI or C-reactive protein), and an inadequate response or intolerance to non-steroidal anti-inflammatory drugs. Patients were randomly allocated to placebo or double-blind ixekizumab 80 mg every 4 weeks (Q4W) or 2 weeks (Q2W), with an 80 mg or 160 mg starting dose. We report a post-hoc analysis of 266 patients with available MRI scans from baseline and week 16. MRI scans were scored using the Spondyloarthritis Research Consortium of Canada (SPARCC) sacroiliac joint structural score (SSS) method independently by two masked readers. Treatment comparisons used analysis of covariance based on observed cases. Correlations were evaluated among changes in SPARCC SSS for erosion, fat lesions, and backfill, and between changes in SPARCC SSS and sacroiliac joint inflammation scores and clinical measures. COAST-X was registered with ClinicalTrials.gov, NCT02757352. FINDINGS: Between Aug 2, 2016, and Jan 29, 2018, 303 patients were enrolled to the COAST-X study. 290 (96%) of 303 participants completed the week 16 visit (95 in the ixekizumab Q4W group, 98 in the ixekizumab Q2W group, and 97 in the placebo group), and MRI scans were available for 266 patients at baseline and week 16 (85 in the ixekizumab Q4W group, 91 in the ixekizumab Q2W group, and 90 in the placebo group). Changes from baseline to week 16 in mean SPARCC SSS for erosion were -0·39 for ixekizumab Q4W (p=0·003 vs placebo), -0·40 for ixekizumab Q2W (p=0·002), and 0·16 for placebo; for fat lesions: 0·16 for ixekizumab Q4W (p=0·013), 0·10 for ixekizumab Q2W (p=0·067), and -0·04 for placebo; and for backfill: 0·21 for ixekizumab Q4W (p=0·011), 0·22 for ixekizumab Q2W (p=0·006), and -0·10 for placebo. Ankylosis did not change. Effects of ixekizumab versus placebo on structural changes were most pronounced in patients with baseline inflammation in the sacroiliac joints. Changes from baseline at week 16 in erosion, fat lesions, and backfill were correlated. INTERPRETATION: Although the clinical relevance is not yet clear, patients with non-radiographic axial spondyloarthritis receiving ixekizumab had significant reductions in erosions and increases in fat lesions and backfill in the sacroiliac joints versus placebo at week 16, suggesting an early repair process with ixekizumab treatment. FUNDING: Eli Lilly and Company.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Maksymowych WP, Baraliakos X, Lambert RG, et al. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis. Lancet Rheumatol. 2022. PMID: 38288892. doi:10.1016/S2665-9913(22)00185-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。